Gilead makes an impact on every stage of the continuum of care, from the laboratory, to the clinic, to access to medicines in all corners of the world. We asked our employees what that means to them.
One of the great joys of working at Gilead is that all day I'm talking to some of the most brilliant minds, from scientists, to lawyers, to marketing people. And we're all focused on one thing. We're focused on the patients, and how the patient is going to be impacted by our work.
And while we're working on the development of one drug, we're already thinking about three or four other drugs down the line that might be better than the current drug that we're developing.
I wanted to work at Gilead, not only because I lost my mother when I was young, but because I wanted to eliminate one life-threatening disease from this world.
Gilead's commitment to oncology I think really is... it’s is very similar to what it was in virology.
And the organization is committed to doing the same thing by building on science foundation blocks, and applying what our knowledge and expertise are to solve the problem.
My mom has CLL, and it's really important to me to-to be -- that Gilead is working on CLL, as a therapeutic area. And, it's great for me to be able to learn about the disease and, you know, talk to my mom about it. And my mom is so proud.
I'm from West African descent. I've been to Ghana a couple of times and I've seen first-hand how HIV has affected lives there. We've been a market leader for many, many years. And to be able to be part of that success story is really what drove me here.
One of the key projects I've been working on recently is to really help folks understand why it's so important to have broad access to HIV and HCV therapies, and that ultimately that provides long-term benefit, not only to the patient but to the community and to society at large.
70 percent of patients with hepatitis C are actually from Africa and Southeast Asia and Latin America…. I'm hoping that with Gilead's innovative product in hepatitis C, we're able to bring it to the countries that need it the most.
What we have done for the HCV treatment… making them available as soon as possible, to patients that needed them, has profoundly transformed the pharma environment.
I think we’ll see, similar to what we saw with HIV with the big push to reach the undiagnosed, we'll see that in a couple years on HCV, but we want to be at the forefront, to be helping people and helping systems behind the scenes, understand what they can do today to be ready for tomorrow.
When I think about the work that we do, I think about my children. And I think about their generation and the future for them. And I can't help but think that the work that we're doing today at Gilead will leave them with a better future.
Gilead plays a central role in developing single tablet regimens – with one pill once a day, patients can take all of their medication in each dose.
Our liver disease programs focus on expanding treatment options for chronic hepatitis B and C.
Our scientists are applying new knowledge about how cancers grow and spread to potentially enhance and improve cancer therapy.
Our medicines aim to help patients with cardiovascular disease return to their daily activities, and we are exploring potential new indications.
We research and develop treatments for serious respiratory conditions such as influenza, cystic fibrosis and other diseases of the lungs.
Gilead medicines treat severe fungal and parasitic infections, and address vision loss caused by degenerative eye diseases.
The Chronicle of Philanthropy ranked Gilead first among companies in charitable giving. Learn more.
Access earnings press release, webcast link and slides for Gilead’s first quarter 2016 results. View materials.
June 28, 2016
U.S. Food and Drug Administration Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C